Description

(3S)-(7-Bromo-2-Oxo-5-Pyridin-2-Yl-2,3-Dihydro-1H-Benzo[E][1,4]Diazepin-3-Yl)-Propionic Acid Methyl Ester is a high-purity, advanced pharmaceutical intermediate characterized by its complex heterocyclic structure. This compound is of significant value for its role as a key chiral building block in the synthesis of novel therapeutic agents, particularly in central nervous system (CNS) research. It is primarily required by pharmaceutical R&D laboratories and fine chemical manufacturers engaged in the development of next-generation benzodiazepine analogs and other bioactive molecules. Our supply is backed by stringent quality control to ensure batch-to-batch consistency for critical synthetic pathways.

Application

• Pharmaceutical Intermediate: Serves as a critical chiral precursor in the multi-step synthesis of proprietary drug candidates targeting neurological disorders.
• Medicinal Chemistry Research: Used as a scaffold for structure-activity relationship (SAR) studies to develop new compounds with modulated receptor binding profiles.
• Active Pharmaceutical Ingredient (API) Development: Employed in the research and process development stages for potential new benzodiazepine-derived APIs.
• Contract Research & Manufacturing (CRO/CMO): Supplied to organizations specializing in custom synthesis and process optimization for client projects.
• Reference Standard: Can be utilized as an analytical standard for method development and quality control in related compound analysis.

Basic Information

Product Name	(3S)-(7-Bromo-2-Oxo-5-Pyridin-2-Yl-2,3-Dihydro-1H-Benzo[E][1,4]Diazepin-3-Yl)-Propionic Acid Methyl Ester
CAS No.	308242-23-1
Molecular Formula	C20H18BrN3O3
Molecular Weight	428.28 g/mol
Synonyms	Methyl (3S)-7-bromo-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepine-3-propanoate; (S)-Methyl 3-(7-bromo-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propanoate; 308242-23-1; (3S)-3-(Methoxycarbonylethyl)-7-bromo-5-(2-pyridyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
EINECS	Contact for details

Quality Control

Our production of (3S)-(7-Bromo-2-Oxo-5-Pyridin-2-Yl-2,3-Dihydro-1H-Benzo[E][1,4]Diazepin-3-Yl)-Propionic Acid Methyl Ester adheres to rigorous quality testing protocols to ensure compliance with pharmaceutical intermediate standards. Each batch is validated through advanced analytical techniques including HPLC, NMR, and chiral analysis to confirm identity, purity, and enantiomeric excess. Certificates of Analysis (COA) detailing all critical parameters are available upon request, providing full traceability and supporting your regulatory and R&D documentation needs.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). The compound may be light-sensitive and should be handled under appropriate conditions to maintain stability. For long-term storage, consider inert atmosphere conditions.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Chiral Purity (Chiral HPLC)	≥ 99.0% ee
Loss on Drying	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.